Search Results 4981-4990 of 35344 for oral

  1. Oral Cavity & Pharynx. 20.6 reported Mammogram in 2 years. Bladder. 15.1. 0.0. Leukemia. 12.5. 0.0. Target. 80.5%. Pancreas. Brain & ONS. Cervix. Esophagus.

  2. Oral Cavity & Pharynx. 8.0. 2.8. Adults aged 50-75 years who reported. State. Cervix. 5.9. 0.0. Esophagus. 5.2. 6.6 being up-to-date with colorectal cancer ...

  3. Oral Cavity & Pharynx. Uncategorized. 3.0. 1.9 being up-to-date with colorectal cancer screening. 0.8. 1.9. Target. 76.6%. 74.4%. 0.0. 0.0. Data Sources: ...

  4. Oral Cavity & Pharynx. 1.4. 1.1. Target. 76.6%. 74.4%. Uncategorized. 0.0. 0.0. Data Sources: Incidence and Mortality from State Cancer Profiles (for FL, AZ, WI ...

  5. Topotecan (intravenous route) - Side effects & uses - Mayo Clinic

    Also, avoid persons who have taken oral polio vaccine within the past several months. Do not get close to them and do not stay in the same room with them ...

  6. Pediatrics Clinical Trials - Medical Professionals

    The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

  8. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric and Adolescent Medicine · Pediatric Otolaryngology · Physical Medicine ...

  9. Aphasia - Symptoms & causes - Mayo Clinic

    Some conditions, including stroke or head injury, can seriously affect a person's ability to communicate. Learn about this communication disorder and its ...

  10. Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia - Mayo Clinic

    Oral etoposide (up to 200 mg orally per day) may be given as an alternative ... Antileukemic therapy for the treatment of AML (excluding hydroxyurea or oral ...